Article Text

Download PDFPDF

Effectiveness of inhaled corticosteroids in real life on clinical outcomes, sputum cells and systemic inflammation in asthmatics: a retrospective cohort study in a secondary care centre
  1. Sophie F Demarche1,2,
  2. Florence N Schleich1,
  3. Monique A Henket1,
  4. Virginie A Paulus1,
  5. Thierry J Van Hees2,
  6. Renaud E Louis1
  1. 1Department of Respiratory Medicine, CHU Liege, GIGA I³ Research Group, University of Liege, Liège, Belgium
  2. 2Department of Clinical Pharmacy, Center for Interdisciplinary Research on Medicines (CIRM), University of Liege, Liege, Belgium
  1. Correspondence to Sophie F Demarche; sophie.demarche{at}student.ulg.ac.be

Abstract

Objectives The impact of inhaled corticosteroids (ICS) on eosinophilic inflammation in asthma is well established, but their effect in a real-life setting has not been extensively studied. Our purpose was to investigate the effect of ICS on airway and systemic inflammation as well as on clinical outcomes in patients with asthma from clinical practice.

Design, setting and participants We conducted a retrospective analysis on asthmatics from a secondary care centre in whom ICS were initiated/increased (n=101), stopped/decreased (n=60) or remained stable (n=63, used as a control group) between two visits with available sputum and blood cell counts.

Results The median time between both visits ranged from 1 to 2 years. Initiating or increasing ICS (median variation (IQR): 800 (400–1200) µg beclomethasone equivalent dose per day) reduced sputum eosinophils and fractional exhaled nitric oxide (P<0.0001) and to a lesser extent blood eosinophils (P<0.0001), while withdrawing or decreasing ICS (median variation (IQR): 900 (500–1200) µg beclomethasone equivalentdose per day) resulted in increased sputum eosinophils (P=0.008). No change was found in patients with a stable dose. The effectiveness of ICS in improving asthma control, quality of life, forced expiratory volume in 1 s (FEV1), bronchial hyper-responsiveness and exacerbation rate was only observed in the eosinophilic phenotype (sputum eosinophils ≥3%, n=79). In non-eosinophilic asthmatics, stepping-down ICS resulted in an improvement in asthma control and quality of life, without any significant change in FEV1 (n=38).

Conclusions Our results confirm the effectiveness of ICS on eosinophilic inflammation in real life and demonstrate that their clinical benefit seems to be restricted to eosinophilic asthmatics. Our data also support a try for stepping-down ICS in non-eosinophilic asthmatics.

  • asthma
  • therapeutics
  • adult thoracic medicine

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SFD and REL were involved in the conception and design of the study. SFD, FNS, VAP, MAH and REL collected the patients’ data. SFD performed the statistical analysis. SFD, REL and TVH interpreted the data. SFD and REL drafted the manuscript. FNS, VAP, MAH and TVH revised the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

  • Funding This work was supported by a federal grant IAP (’Interuniversity Attraction Poles' programme) P7/30.

  • Competing interests TVH received grants from Amgen, outside the submitted work. REL received grants and personal fees from GSK, Chiesi, Astra Zeneca, Novartis, outside the submitted work.

  • Ethics approval Ethics Committee of the University Hospital of Liege approved this study (reference 2017/97).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.